Challenges in the diagnosis of drug-resistant tuberculosis by GeneXpert MTB/Rif in Nepal

Abstract

Introduction: GeneXpert MTB/Rif assay is an automated, cartridge-based nucleic acid amplification test that can accurately detect both tuberculosis and Rifampicin resistance. Since its introduction, there has been a steady uptake of this technology by the National Tuberculosis Program of Nepal. Nevertheless, a large number of drug-resistant TB cases remains undiagnosed. This study aims to examine the challenges in diagnosis of drug-resistant tuberculosis by the GeneXpert MTB/Rif assay in Nepal and explore the possible solutions.
 Methods: This was a cross-sectional study consisting of two parts – a quantitative part assessing the individual details and a qualitative part assessing the challenges on the diagnosis of drug-resistant TB by GeneXpert MTB/Rif assay. Data were collected from the GeneXpert operators, clinicians and program managers from 16 centers across the country and analyzed by IBM SPSS for Windows v23 and QDA Miner 4 Lite. Descriptive statistics were used to summarize the sociodemographic and other characteristics of the study participants using mean, standard deviation and proportions as appropriate.
 Results: A total of 48 technical manpower participated in the study. The mean age was 39.95 years and a majority of them (77.3%) were male. The major challenges identified were inadequate training, frequent power failure, difficulty in maintaining appropriate steady temperature, module failure which is often not replaced in time, issues with calibration and timely availability of cartridges as well as appropriate ways to store the new cartridges and safe disposal of the used cartridges.
 Conclusion: A number of challenges limit the optimal utilization of GeneXpert MTB/Rif assay warranting action.

Risk Factors of Multi-Drug Resistant Tuberculosis among Tuberculosis Patients in Province 3, Nepal: A case-control study

“…So, the missing cases are the major problem in Nepal (8). There are major challenges for diagnosis of MDR TB in Nepal, such as inadequate training, frequent power failure, difficulty in maintaining an appropriate steady temperature, module failure, which is often not replaced in time, issues with calibration and timely availability of cartridges, as well as appropriate ways to store the new cartridges and safe disposal of the used cartridges (16). From a public health perspective, the MDR-TB growing epidemics will not be controlled merely by the introduction of a few new antibiotics as it is also linked to patient compliance and adequate case management supported by efficient TB programs (17).…”

Comparison of Genexpert MTB/RIF Assay and AFB Smear Microscopy in Diagnosis of Pulmonary Tuberculosis among HIV Patients at a Tertiary Care Hospital

“…The GeneXpert MTB / RIF Assay is a unique hands-free integrated cartridge with incorporated chemicals and reagents for sample processing and hemi-nested real-time PCR analysis in a sequential manner for tuberculosis diagnosis and quick RIF resistance detection in clinical samples on GeneXpert platform. 9 This diagnostic has advantages of high sensitivity (79%) specificity (99%) 10 , as well as determining rifampicin resistance as an indicator for MDR TB and providing the result in two hours. It is simple to conduct and is safe as it produces no cultivable aerosols.…”

Virus Bakteri sebagai Terapi untuk Penyakit Infeksi

“…Resistensi bakteri terhadap antibiotik merupakan masalah serius yang harus menjadi perhatian para penyedia layanan kesehatan. Bakteri penyebab infeksi yang resisten terhadap sejumlah antibiotik telah ditemukan di seluruh dunia, sebagai contoh: multidrug-resistant tuberculosis (MDR-TB), extensively drugresistance tuberculosis (XDR-TB) (Shrestha et al, 2018), methicillin-resistance Staphylococcus aureus (MRSA) (Acharya et al, 2019). Kondisi tersebut akan berdampak secara ekonomi dengan meningkatnya biaya pengobatan karena lamanya perawatan pasien, serta berdampak terhadap kejadian mortalitas dan morbiditas akibat infeksi bakteri yang resisten.…”